PRGO:NYE-Perrigo Company plc (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 27.01

Change

0.00 (0.00)%

Market Cap

USD 12.59B

Volume

1.45M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-10 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+2.65 (+1.66%)

USD 66.32B
HLN Haleon plc

-0.03 (-0.28%)

USD 45.41B
TAK Takeda Pharmaceutical Co Ltd A..

-0.17 (-1.18%)

USD 43.84B
RDY Dr. Reddy’s Laboratories Ltd..

+0.53 (+3.96%)

USD 11.39B
ELAN Elanco Animal Health

+0.86 (+7.19%)

USD 4.28B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.19 (+2.56%)

USD 3.25B
BHC Bausch Health Companies Inc

+0.19 (+4.14%)

USD 1.60B
CPHI China Pharma Holdings Inc

+0.13 (+6.18%)

USD 4.61M
YCBD cbdMD Inc

+0.02 (+1.60%)

USD 1.44M
EBS Emergent Biosolutions Inc

+0.19 (+3.36%)

N/A

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
LIMI Themes Lithium & Battery .. 10.46 % 0.00 %

+1.10 (+4.78%)

USD 0.44M
XMET:AU BetaShares Energy Transit.. 4.93 % 0.00 %

+0.22 (+4.78%)

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.24 (+4.78%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.71 (+4.78%)

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 0.00 % 0.00 %

+0.25 (+4.78%)

CAD 0.81B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A
ION Proshares S&P Global Core.. 0.00 % 0.00 %

+0.60 (+4.78%)

USD 2.31M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.06% 64% D 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.06% 64% D 79% B-
Trailing 12 Months  
Capital Gain -12.05% 21% F 22% F
Dividend Return 2.70% 50% F 50% F
Total Return -9.35% 21% F 22% F
Trailing 5 Years  
Capital Gain -49.42% 38% F 8% B-
Dividend Return 9.12% 40% F 20% F
Total Return -40.30% 46% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -12.98% 7% C- 5% F
Dividend Return -10.47% 13% F 6% D-
Total Return 2.52% 71% C- 56% F
Risk Return Profile  
Volatility (Standard Deviation) 8.05% 100% F 83% B
Risk Adjusted Return -130.01% 7% C- N/A F
Market Capitalization 12.59B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector